Is Ascendis Pharma A/S (ASND) Stock About to Get Hot Friday?

Ascendis Pharma A/S (ASND) stock is down 6.95% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Ascendis Pharma A/S has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ASND!

See Full ASND Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ASND Stock Today?

Ascendis Pharma A/S (ASND) stock is trading at $105.01 as of 2:02 PM on Friday, Apr 22, a decline of -$1.04, or -0.98% from the previous closing price of $106.05. The stock has traded between $104.80 and $108.10 so far today. Volume today is light. So far 170,382 shares have traded compared to average volume of 606,296 shares. To screen for more stocks like Ascendis Pharma A/S click here.

More About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China. Click Here to get the full Stock Report for Ascendis Pharma A/S stock.